Conjoint analysis of a new Chemotherapy: willingness to pay and preference for the features of raltitrexed versus standard therapy in advanced Colorectal Cancer.

Objective: To estimate the willingness to pay for a new chemotherapy, raltitrexed (Tomudex™1) over conventional therapy with fluorouracil plus leucovorin (FU-LV) from the perspective of patients with advanced colorectal cancer. The study was part of the product’s reimbursement application in Australia.